On April 23, 2026 Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, reported that two latest clinical study results of its Nectin-4-targeting ADC 9MW2821 in combination with toripalimab for urothelial carcinoma will be presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, USA from May 29 to June 2, 2026 (local time), as an oral presentation and a poster presentation, respectively.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation

Title: Bulumtatug fuvedotin (BFv; 9MW2821) plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Follow-up results from a phase 1b/2 study.

Abstract Number for Publication: 4518

Presenter: Prof. Sheng Xinan, Chief Physician, doctoral supervisor, Dept. of Urologic Oncology (Beijing Cancer Hospital)

Session Date and Time: 6/1/2026 8:00AM-9:30AM CDT

Poster Presentation

Title: Bulumtatug fuvedotin (BFv; 9MW2821) plus toripalimab in perioperative patients with muscle-invasive bladder cancer (MIBC): Results of cohort A from a phase 2 study.

Abstract Number for Publication: 4609

Principal Investigator: Prof. Liu Zhuowei, Chief Physician, Dept. of Urology (Sun Yat-sem University Cancer Center)

Session Date and Time: 5/31/2026 9:00AM-12:00PM CDT

(Press release, Mabwell Biotech, APR 23, 2026, View Source;mabwell-to-present-latest-clinical-data-on-9mw2821-combined-with-toripalimab-for-urothelial-carcinoma-in-oral-and-poster-presentations-302751449.html [SID1234664734])